Skip to content

Updating Preventive and Treatment Guidelines for Hypoglycemia in Individuals Living with Type 1 Diabetes

Type 1 Diabetes

The REMODAL trial is a randomized crossover study aiming to update treatment guidelines for mild hypoglycemia in people with Type 1 diabetes using continuous glucose monitoring (CGM) technology. The study will assess whether treating mild hypoglycemia proactively (at a glucose threshold of 5.0 mmol/L) with lower doses of carbohydrate (CHO) is more effective than the traditional reactive approach (treatment at \< 4.0 mmol/L). The goal is to reduce hypoglycemia frequency and improve quality of life, while minimizing caloric intake and rebound hyperglycemia.

null

Participation Requirements

  • Sex:

    ALL

  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria:

* Adults aged 18 years and older
* Clinical diagnosis of Type 1 diabetes for at least 1 year
* Currently treated with multiple daily insulin injections (MDI), continuous subcutaneous insulin infusion (CSII), or automated insulin delivery (AID) systems
* HbA1c level below 9.0%
* Equal distribution of male and female participants, as well as MDI/CSII and AID users

Exclusion Criteria:

* Gastroparesis
* Significant cardiac rhythm abnormalities
* Clinically significant microvascular complications such as nephropathy (eGFR \< 40 ml/min) or severe proliferative retinopathy
* Diagnosis of epilepsy
* Pregnancy or currently breastfeeding
* Severe hypoglycemic episode within 1 month prior to inclusion
* Macrovascular events or uncorrected hypokalemia (K+ \< 3.5 mmol/L) within 3 months prior to inclusion
* Anticipated treatment changes during the trial period
* Inability to provide informed consent

Study Location

Institut de recherches cliniques de Montréal
Institut de recherches cliniques de Montréal
Montreal, Quebec
Canada

Contact Study Team

Montreal Clinical Research Institute
Montreal Clinical Research Institute
Montreal, Quebec
Canada

Contact Study Team

Study Sponsored By
Institut de Recherches Cliniques de Montreal
Participants Required
More Information
Study ID: NCT06683391